We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

49 hedge funds and large institutions have $121M invested in VanEck Pharmaceutical ETF in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital invested

Capital invested by funds: $79M → $121M (+$42.4M)

7.18% more ownership

Funds ownership: 23% → 30.18% (+7.2%)

0% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 16

9% less funds holding

Funds holding: 54 → 49 (-5)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

Holders
49
Holders Change
-5
Holders Change %
-9.26%
% of All Funds
1.42%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
2
Increased
16
Reduced
16
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$24.9M
2
Barclays
Barclays
United Kingdom
+$15.5M
3
Citigroup
Citigroup
New York
+$3.12M
4
UCFA
United Capital Financial Advisors
Texas
+$3.02M
5
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$2.96M

Top Sellers

Rank Fund Capital Flow
1
CC
Columbia Capital
California
-$3.25M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.09M
3
B
Baird
Wisconsin
-$1.43M
4
AP
Advisors Preferred
Maryland
-$1.32M
5
RJA
Raymond James & Associates
Florida
-$1.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
26
Redmile Group
California
$413K – – –
BPC
27
Banque Pictet & Cie
Switzerland
$407K – – –
FPCM
28
Financial Partners Capital Management
New York
$383K – – –
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$363K -$2.09M -33,814 -86%
Bank of Montreal
30
Bank of Montreal
Ontario, Canada
$353K +$24.8K +400 +8%
KFC
31
Klingenstein Fields & Co
New York
$305K – – –
JWM
32
Jacobus Wealth Management
Wisconsin
$303K – – –
FMW
33
Farr Miller & Washington
District of Columbia
$254K – – –
OPCM
34
Osborne Partners Capital Management
California
$242K – – –
LTFS
35
Ladenburg Thalmann Financial Services
Florida
$236K -$81.7K -1,319 -26%
MA
36
MUFG Americas
New York
$163K -$8.36K -135 -5%
TCM
37
Tradewinds Capital Management
Washington
$135K -$9.91K -160 -7%
PNC Financial Services Group
38
PNC Financial Services Group
Pennsylvania
$132K -$8.36K -135 -6%
MFS
39
MSI Financial Services
Massachusetts
$112K +$28.1K +453 +35%
GT
40
Glenmede Trust
Pennsylvania
$75K – – –
Wells Fargo
41
Wells Fargo
California
$64K – – –
Deutsche Bank
42
Deutsche Bank
Germany
$63K +$31K +500 +100%
HCM
43
Highlander Capital Management
New Jersey
$59.8K +$2.48K +40 +4%
Citadel Advisors
44
Citadel Advisors
Florida
$57K -$90.1K -1,455 -62%
NES
45
New England Securities
New York
$57K +$11.2K +181 +25%
DADC
46
D.A. Davidson & Co
Montana
$46K – – –
FAM
47
Formidable Asset Management
Ohio
$13K – – –
WEC
48
Winslow Evans & Crocker
Massachusetts
$6.36K – – –
Creative Planning
49
Creative Planning
Kansas
$2K +$1.86K +30 New
CC
50
Columbia Capital
California
– -$3.25M -52,383 Closed
1
2
3

PPH Hedge Fund Activity: Q3 2014 in Review

49 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2014, worth a combined $121M — up 54% from $79M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of PPH and 2 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 16 added.

The largest buyer was Goldman Sachs, adding an estimated $24.9M. The largest seller was Columbia Capital, exiting entirely with an estimated $3.25M sold.

  • 49 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2014, down from 54 in Q2 2014.
  • Funds reported $121M of VanEck Pharmaceutical ETF stock for Q3 2014, up 54% quarter-over-quarter.
  • 2 funds opened new VanEck Pharmaceutical ETF positions in Q3 2014 and 7 closed out, a net change of -5 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q3 2014 was Goldman Sachs, an estimated $24.9M added.
  • The largest VanEck Pharmaceutical ETF seller in Q3 2014 was Columbia Capital, an estimated $3.25M sold.

Based on aggregated 13F filings for Q3 2014.